Document is current
Any future updates will be listed below
-
Authors
He, Mi https://orcid.org/0000-0002-8271-6672
Soni, Bhavesh
Schwalie, Petra C
Hüsser, Tamara
Waltzinger, Caroline
De Silva, Duvini
Prinz, Ylva
Krümpelmann, Laura
Calabro, Samuele
Matos, Ines
Trumpfheller, Christine
Bacac, Marina
Umaña, Pablo
Levesque, Mitchell P
Dummer, Reinhard https://orcid.org/0000-0002-2279-6906
van den Broek, Maries https://orcid.org/0000-0002-9489-3692
Gasser, Stephan
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03906526 at ClinicalTrials.govnct04460456 at ClinicalTrials.govDocuments that mention this clinical trial
Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells
https://doi.org/10.1136/jitc-2021-004268
nct02431559 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
393 A phase 1/2 study of SBT6050 combined with trastuzumab deruxtecan (T-DXd) or trastuzumab and tucatinib with or without capecitabine in patients with HER2-expressing or HER2-amplified cancers
https://doi.org/10.1136/jitc-2021-sitc2021.393
Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells
https://doi.org/10.1136/jitc-2021-004268
Where does ISAC (immune-stimulating antibody conjugates) go from here?
https://doi.org/10.1136/jitc-2025-012500
nct01836029 at ClinicalTrials.govDocuments that mention this clinical trial
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine
https://doi.org/10.1016/j.ygyno.2015.12.030
Ovarian cancer and the immune system — The role of targeted therapies
https://doi.org/10.1016/j.ygyno.2016.05.007
Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells
https://doi.org/10.1136/jitc-2021-004268
nct02614456 at ClinicalTrials.govDocuments that mention this clinical trial
Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells
https://doi.org/10.1136/jitc-2021-004268
nct02834052 at ClinicalTrials.govDocuments that mention this clinical trial
Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells
https://doi.org/10.1136/jitc-2021-004268
nct01976585 at ClinicalTrials.govDocuments that mention this clinical trial
Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells
https://doi.org/10.1136/jitc-2021-004268
Lifting the innate immune barriers to antitumor immunity
https://doi.org/10.1136/jitc-2020-000695
nct03732547 at ClinicalTrials.govDocuments that mention this clinical trial
Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming
https://doi.org/10.1136/jitc-2023-007198
Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells
https://doi.org/10.1136/jitc-2021-004268
Documents that mention this clinical trial
Integrated single-cell transcriptome and TCR profiles of hepatocellular carcinoma highlight the convergence on interferon signaling during immunotherapy
https://doi.org/10.1136/jitc-2024-010534
Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells
https://doi.org/10.1136/jitc-2021-004268
- License Information
